Heart drug Pelacarsen misses primary goal despite cutting Lp(a) levels
Pelacarsen, a heart medication intended to reduce lipoprotein(a), has not met its goals in a key clinical study. While the drug was successful in significantly decreasing Lp(a) levels, it failed to lower the incidence of strokes, heart attacks, or deaths related to cardiovascular issues. This result complicates existing theories regarding Lp(a) and underscores how difficult it is to prevent heart-related diseases.
by shortkt.com✓